Updates are available Correction dated 2022-04-29
Click to view Correction: https://doi.org/10.1038/s41391-022-00539-0
-
Authors
Pan, Elizabeth
Shaya, Justin
Madlensky, Lisa
Randall, J. Michael
Javier-Desloges, Juan
Millard, Frederick E.
Rose, Brent
Parsons, J. Kellogg
Nielsen, Sarah M.
Hatchell, Kathryn E. https://orcid.org/0000-0003-0849-7018
Esplin, Edward D. https://orcid.org/0000-0001-9205-3756
Nussbaum, Robert L.
Weise, Nicole
Murphy, James
Martinez, Maria Elena
McKay, Rana R. https://orcid.org/0000-0002-0581-7963
- License Information
-
More Information
Article History
Received: 10 December 2021
Revised: 4 February 2022
Accepted: 14 February 2022
First Online: 28 February 2022
Change Date: 29 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41391-022-00539-0
Competing interests
: RRM received research funding from Bayer, Pfizer, Tempus; serves on Advisory Board for AstraZeneca, Bayer, Bristol Myers Squibb, Calithera, Exelixis, Janssen, Merck, Novartis, Pfizer, Sanofi, Tempus; is a consultant for Dendreon, Myovant, Sorrento Therapeutics, Vividion; serves on the molecular tumor board at Caris. RLN is a consultant and stockholder in Maze Therapeutics and Genome Medical and a consultant for Pfizer Pharmaceuticals. SMN, KEH, EDE, and RLN are employees and stockholders of Invitae.
